What is the Current Scope of Research Assessing Patients' and Clinicians' Perspectives on Clozapine Treatment? A Comprehensive Scoping Review

Overview

Journal BMJ Open

Date 2025 Jan 17

PMID 39819922

Authors

Michelle Iris Jakobsen

Julie Perrine Schaug

Ole Jakob Storebo

Stephen F Austin

Jimmi Nielsen

Erik Simonsen

Affiliations

Soon will be listed here.

Abstract

Objectives: Clozapine is continuously underused. The existing systematic reviews addressing barriers to clozapine prescribing primarily focus on clinical staff's attitudes and perceived barriers to prescribing. However, a preliminary literature search revealed additional literature on the subject not previously included in systematic reviews, including literature on patient perspectives. A scoping review is warranted to map the scope of primary studies on patients' and/or clinicians' perspectives on clozapine treatment and to identify gaps in research.

Design: A scoping review was designed and reported in accordance with established guidelines for scoping reviews.

Data Sources: The electronic databases Cochrane Library, CINAHL, Web of Science, PsycINFO, MEDLINE, EMBASE, Google Scholar and two grey literature databases were searched. Furthermore, citation tracking of selected studies was undertaken.

Eligibility Criteria: We included primary, empirical studies reporting clinicians' and/or patients' perspectives on clozapine treatment. No limitation was set for the year of publication or type of primary study.

Data Extraction And Synthesis: Two researchers independently screened for studies, extracted the data and coded the content. Findings were summarised visually and narratively.

Results: 146 studies were included. Most studies reported on patients' or clinicians' perspectives on active clozapine treatment or on clinicians' perspectives on barriers to clozapine initiation in general. Three gaps in research were identified: (1) clozapine-eligible, yet clozapine-naïve, patients' attitudes towards clozapine commencement, (2) clinicians' reasons for clozapine withholding and perceived facilitators of clozapine treatment in specific patient-cases and (3) patient and clinician perspectives on clozapine discontinuation, continuation and rechallenge in specific patient cases.

Conclusions: Research on clozapine perspectives tends to repeat itself. Future studies addressing the identified gaps in evidence could provide the insights needed to optimise clozapine utilisation.

References

Butler E, Pillinger T, Brown K, Borgan F, Bowen A, Beck K . Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. Br J Psychiatry. 2022; 221(6):740-747. DOI: 10.1192/bjp.2022.47. View

Takeuchi H, Borlido C, Sanches M, Teo C, Harber L, Agid O . Adherence to clozapine vs. other antipsychotics in schizophrenia. Acta Psychiatr Scand. 2020; 142(2):87-95. DOI: 10.1111/acps.13208. View

Haw C, Stubbs J . Medication for borderline personality disorder: a survey at a secure hospital. Int J Psychiatry Clin Pract. 2011; 15(4):280-5. DOI: 10.3109/13651501.2011.590211. View

Mortimer A, Singh P, Shepherd C, Puthiryackal J . Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. Clin Schizophr Relat Psychoses. 2010; 4(1):49-55. DOI: 10.3371/CSRP.4.1.4. View

Law A, Croucher M . Prescribing trends and safety of clozapine in an older persons mental health population. Int Psychogeriatr. 2019; 31(12):1823-1829. DOI: 10.1017/S1041610219000255. View

Peters M, Marnie C, Tricco A, Pollock D, Munn Z, Alexander L . Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020; 18(10):2119-2126. DOI: 10.11124/JBIES-20-00167. View

Balestrieri M, Di Sciascio G, Isola M, Lomonaco E, Maso E, Merli R . Drug attitude and subjective well-being in antipsychotic treatment monotherapy in real-world settings. Epidemiol Psichiatr Soc. 2009; 18(2):114-8. View

Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A . Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res. 2000; 43(2-3):135-45. DOI: 10.1016/s0920-9964(99)00154-1. View

Freudenreich O, Cather C, Evins A, Henderson D, Goff D . Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry. 2004; 65(10):1372-6. DOI: 10.4088/jcp.v65n1012. View

10.

Friedman J, Goldstein S, Jacques C . Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. Clin Neuropharmacol. 1998; 21(5):285-8. View

11.

Thien K, ODonoghue B . Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: A literature review. Early Interv Psychiatry. 2018; 13(1):18-23. DOI: 10.1111/eip.12683. View

12.

Rezaie L, Nazari A, Safari-Faramani R, Shohaimi S, Khazaie H . Iranian psychiatrists' attitude towards clozapine use for patients with treatment-resistant schizophrenia: a nationwide survey. BMC Psychiatry. 2022; 22(1):534. PMC: 9357336. DOI: 10.1186/s12888-022-04179-5. View

13.

Grace J, Szarowicz R . The clozapine access project. Psychiatr Serv. 2001; 52(1):108. DOI: 10.1176/appi.ps.52.1.108-a. View

14.

Jakobsen M, Schaug J, Nielsen J, Simonsen E . Antipsychotic prescribing practices for outpatients with schizophrenia and reasons for non-clozapine treatment - Data from a Danish quality assessment audit. Nord J Psychiatry. 2023; 77(5):481-490. DOI: 10.1080/08039488.2022.2160878. View

15.

Gee S, Shergill S, Taylor D . Long-term follow-up of clozapine prescribing. J Psychopharmacol. 2018; 32(5):552-558. DOI: 10.1177/0269881118760666. View

16.

Kelly D, Ben-Yoav H, Payne G, Winkler T, Chocron S, Kim E . Blood Draw Barriers for Treatment with Clozapine and Development of a Point-of-Care Monitoring Device. Clin Schizophr Relat Psychoses. 2015; 12(1):23-30. DOI: 10.3371/CSRP.KEBE.070415. View

17.

Naber D, Riedel M, Klimke A, Vorbach E, Lambert M, Kuhn K . Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand. 2005; 111(2):106-15. DOI: 10.1111/j.1600-0447.2004.00486.x. View

18.

Thalayasingam S, Alexander R, Singh I . The use of clozapine in adults with intellectual disability. J Intellect Disabil Res. 2004; 48(Pt 6):572-9. DOI: 10.1111/j.1365-2788.2004.00626.x. View

19.

Pere J, Bourdeix I, Bourdain M . [Clozapine (Leponex) in France]. Encephale. 1992; 18 Spec No 3:427-32. View

20.

Jakobsen M, Austin S, Storebo O, Nielsen J, Simonsen E . Non-prescribing of clozapine for outpatients with schizophrenia in real-world settings: The clinicians' perspectives. Schizophrenia (Heidelb). 2023; 9(1):91. PMC: 10746712. DOI: 10.1038/s41537-023-00423-3. View